Key Facts Surrounding This News Item
- BTAI had returned 0.00% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.
More Info About BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation. View our full BTAI ticker page with ratings, news, and more.